- Home
- BRT vs BCYC Comparison
BRT vs BCYC Comparison
Compare BRT & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | BCYC |
|---|---|---|
| Founded | 1972 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.2M | 291.8M |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BRT | BCYC |
|---|---|---|
| Price | $13.92 | $3.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $19.75 | $13.90 |
| AVG Volume (30 Days) | 35.7K | ★ 366.4K |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $97,028,000.00 | N/A |
| Revenue This Year | $3.82 | N/A |
| Revenue Next Year | $5.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $13.18 | $3.61 |
| 52 Week High | $16.50 | $9.16 |
Technical Indicators
Market Signals| Indicator | BRT | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 36.99 | 35.07 |
| Support Level | $13.18 | N/A |
| Resistance Level | $14.87 | $4.51 |
| Average True Range (ATR) | 0.29 | 0.16 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 16.67 | 7.64 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.